PX-12
| Code | Size | Price |
|---|
| AG-CR1-3739-M001 | 1 mg | £35.00 |
Quantity:
| AG-CR1-3739-M005 | 5 mg | £65.00 |
Quantity:
| AG-CR1-3739-M025 | 25 mg | £175.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Documents
Further Information
Alternate Names/Synonyms:
IV-2; 2-[(1-Methylpropyl)dithio]-1H-imidazole
Appearance:
White to off-white powder.
CAS:
141400-58-0
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Handling Advice:
Keep cool and dry.
Hazards:
H315, H319, H335
InChi:
InChI=1S/C7H12N2S2/c1-3-6(2)10-11-7-8-4-5-9-7/h4-6H,3H2,1-2H3,(H,8,9)
InChiKey:
BPBPYQWMFCTCNG-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 141400-58-0. Formula: C7H12N2S2. MW: 188.3. PX-12 is a competitive, irreversible inhibitor of thioredoxin 1 (Trx1), acting by binding to Cys73 of this enzyme.
High levels of Trx-1 have been associated with colorectal, gastric and lung cancers. PX-12 stimulates apoptosis, down-regulates HIF-1alpha, vascular endothelial growth factor (VEGF) and iNOS, and consequently inhibits proliferation and tumor growth in animal models. It has also been reported to inhibit tubulin polymerization in vitro, induce cell cycle arrest at G2/M phase and inhibit growth, migration and invasion of several cancer cell lines.
PX-12 shows antiviral activity against HIV-1, by inhibiting the enzymatic activity of Trx1 and the Trx1-dependent disulfide reduction of gp120. Microtubule polymerization and formation of acetylated microtubules are inhibited as well, activities shown to be required for HIV-1 life cycle propagation.
PX-12 has broad spectrum antimicrobial activity targeting the thioredoxin system of bacterial, fungal, protozoan and helminth pathogens without significant toxicity to the host.
PX-12 potentially inhibits the 33.8-kDa Main protease (Mpro)/3C-like protease of SARS-CoV-2, consequently inhibiting viral transcription and replication and possibly inhibiting spread of COVID-19.
MDL:
MFCD18086851
Molecular Formula:
C7H12N2S2
Molecular Weight:
188.3
Package Type:
Vial
Precautions:
P305+P351+P338, P302+P352, P305+P351+P338
Product Description:
PX-12 is a competitive, irreversible inhibitor of thioredoxin 1 (Trx1), acting by binding to Cys73 of this enzyme. High levels of Trx-1 have been associated with colorectal, gastric and lung cancers. PX-12 stimulates apoptosis, down-regulates HIF-1alpha, vascular endothelial growth factor (VEGF) and iNOS, and consequently inhibits proliferation and tumor growth in animal models. It has also been reported to inhibit tubulin polymerization in vitro, induce cell cycle arrest at G2/M phase and inhibit growth, migration and invasion of several cancer cell lines. PX-12 shows antiviral activity against HIV-1, by inhibiting the enzymatic activity of Trx1 and the Trx1-dependent disulfide reduction of gp120. Microtubule polymerization and formation of acetylated microtubules are inhibited as well, activities shown to be required for HIV-1 life cycle propagation. PX-12 has broad spectrum antimicrobial activity targeting the thioredoxin system of bacterial, fungal, protozoan and helminth pathogens without significant toxicity to the host. PX-12 potentially inhibits the 33.8-kDa Main protease (Mpro)/3C-like protease of SARS-CoV-2, consequently inhibiting viral transcription and replication and possibly inhibiting spread of COVID-19.
Purity:
>98% (HPLC)
Signal word:
Warning
SMILES:
CC(CC)SSC1=NC=CN1
Solubility Chemicals:
Soluble in DMSO, ethanol or DMF (all 15mg/ml). Slightly soluble in water (~1mg/ml).
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Reversible inhibition of human thioredoxin reductase activity by cytotoxic alkyl 2-imidazolyl disulfide analogues: J.E. Oblong, et al.; Cancer Chemother. Pharmacol. 34, 434 (1994) | The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation: S.J. Welsh, et al.; Mol. Cancer Ther. 2, 235 (2003) | The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma: A.F. Baker, et al.; J. Lab. Clin. Med. 147, 83 (2006) | Drug evaluation: the thioredoxin inhibitor PX-12 in the treatment of cancer: C.M. Galmarini; Curr. Opin. Investig. Drugs 7, 1108 (2006) (Review) | 2-[(1-methylpropyl)dithio]-1H-imidazole inhibits tubulin polymerization through cysteine oxidation: K. Huber, et al.; Mol. Cancer Ther. 7, 143 (2008) | PX-12 inhibits the growth of A549 lung cancer cells via G2/M phase arrest and ROS-dependent apoptosis: B.R. You, et al.; Int. J. Oncol. 44, 301 (2014) | PX-12 induces apoptosis in Calu-6 cells in an oxidative stress-dependent manner: B.R. You, et al.; Tumour Biol. 36, 2087 (2015) | Thioredoxin-1 inhibitor, 1-methylpropyl 2-imidazolyl disulfide, inhibits the growth, migration and invasion of colorectal cancer cell lines: F. Wang, et al.; Oncol. Rep. 33, 967 (2015) | Repurposing Auranofin, Ebselen, and PX-12 as Antimicrobial Agents Targeting the Thioredoxin System: H.C. May, et al.; Front. Microbiol. 9, 336 (2018) | Inhibition of the thioredoxin system by PX-12 (1-methylpropyl 2-imidazolyl disulfide) impedes HIV-1 infection in TZM-bl cells: M. Lundberg, et al.; Sci. Rep. 9, 5656 (2019) | Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors: Z. Jin, et al.; Nature 582, 289 (2020)